Our latest articles
With phase 3 data approaching, it should soon become clear whether Bridgebio’s amyloidosis project really has an edge over Pfizer’s Vyndaqel.
Quell should soon join Sangamo in the clinic, while a number of engineered Treg players are at the preclinical stage.
The group gets a long-awaited win in kidney disease, but sales potential is hard to call.
2021 rounds off with key FDA decisions for Argenx, Calliditas and Merck, while Novartis will be hoping for an early Leqvio verdict.
Look out Amryt: Krystal’s topical gene therapy is gaining ground.
Amid cautionary tales of other highly valued unpartnered assets, efgartigimod approaches its US date with destiny.
Efficacy of Merck/Ridgeback’s molnupiravir shows an alarming fall-off, just as a US regulatory panel review beckons.
Roche, its coffers full from coronavirus test sales, ups its research spending – but Baxter cuts back.
Could Gilead soon be looking for a new partner for its long-acting project lenacapavir?
The sellside expects the world’s leading medtech to be outpaced by its rivals. Divestments might allow the group to defy this destiny.